LALuiz Stark Aroeira

Luiz Stark Aroeira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Luiz Stark Aroeira has a total of 168 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Discrimination of Etiologically Different Cholestasis by Modeling Proteomics Datasets

    by Laura Guerrero, Jorge Vindel-Alfageme, Loreto Hierro, Luiz Stark, David Vicent, Carlos Óscar S. Sorzano, Fernando J. Corrales

    Cholestasis is characterized by disrupted bile flow from the liver to the small intestine. Although etiologically different cholestasis displays similar symptoms, diverse factors can contribute to the progression of the disease and determine the appropriate therapeutic option. Therefore, stratifying cholestatic patients is essential for the development of tailor-made treatment strategies. Here, we have analyzed the liver proteome from cholestatic patients of different etiology. In total, 7161 proteins were identified and quantified, of which 263 were differentially expressed between control and cholestasis groups. These differential proteins point to deregulated cellular processes that explain part of the molecular framework of cholestasis progression. However, the clustering of different cholestasis types was limited. Therefore, a machine learning pipeline was designed to identify a panel of 20 differential proteins that segregate different cholestasis groups with high accuracy and sensitivity. In summary, proteomics combined with machine learning algorithms provides valuable insights into the molecular mechanisms of cholestasis progression and a panel of proteins to discriminate across different types of cholestasis. This strategy may prove useful in developing precision medicine approaches for patient care.


  • Citrin deficiency: Early severe cases in a European country

    by Lorena Fernández Tomé, Luiz Guilherme Stark Aroeira, Gema Muñoz Bartolo, Angela de la Vega Bueno, Carmen Camarena Grande, Esteban Frauca Remacha, Dolores Lledín Barbancho, María Alós Díez, María José Quiles Blanco, Laura Guerra, et al.


  • Open Access

    Sensitive and non-invasive method for the in vivo analysis of membrane permeability in small animals

    by Andrea Fernandez-Carrera, Eva Vigo, Carla Regueiro-Rodríguez, África González-Fernández, David Olivieri, Luiz S Aroeira


  • Open Access

    TGF‐Beta Blockade Increases Renal Inflammation Caused by the C‐Terminal Module of the CCN2

    by Raquel Rodrigues-Díez, Sandra Rayego-Mateos, Macarena Orejudo, Luiz Stark Aroeira, Rafael Selgas, Alberto Ortiz, Jesús Egido, Marta Ruiz-Ortega

    The CCN family member 2 (CCN2, also known as connective tissue growth factor) may behave as a risk biomarker and a potential therapeutic target for renal disease. CCN2 participates in the regulation of inflammation and fibrosis. TGF‐β is considered the main fibrogenic cytokine; however, in some pathological settings TGF‐β also has anti‐inflammatory properties. CCN2 has been proposed as a downstream profibrotic mediator of TGF‐β, but data on TGF‐β role in CCN2 actions are scarce. Our aim was to evaluate the effect of TGF‐β blockade in CCN2‐mediated experimental renal damage. Systemic administration of the C‐terminal module of CCN2 to mice caused sustained renal inflammation. In these mice, TGF‐β blockade, using an anti‐TGF‐β neutralizing antibody, significantly increased renal expression of the NGAL (a kidney injury biomarker), kidney infiltration by monocytes/macrophages, and upregulation of MCP‐1 expression. The anti‐inflammatory effect of TGF‐β seems to be mediated by a dysregulation of the systemic Treg immune response, shown by decreased levels of circulating CD4+/Foxp3+Treg cells. Our experimental data support the idea that TGF‐β exerts anti‐inflammatory actions in the kidney and suggest that it is not an optimal therapeutic target.


  • Open Access

    Paricalcitol Reduces Peritoneal Fibrosis in Mice through the Activation of Regulatory T Cells and Reduction in IL-17 Production

    by Guadalupe T González-Mateo, Vanessa Fernández-Míllara, Teresa Bellón, Georgios Liappas, Marta Ruiz-Ortega, Manuel López-Cabrera, Rafael Selgas, Luiz S Aroeira

    Fibrosis is a significant health problem associated with a chronic inflammatory reaction. The precise mechanisms involved in the fibrotic process are still poorly understood. However, given that inflammation is a major causative factor, immunomodulation is a possible therapeutic approach to reduce fibrosis. The vitamin D receptor (VDR) that is present in all hematopoietic cells has been associated with immunomodulation. We investigated whether the intraperitoneal administration of paricalcitol, a specific activator of the VDR, modulates peritoneal dialysis fluid (PDF)-induced peritoneal fibrosis. We characterized the inflammatory process in the peritoneal cavity of mice treated or not treated with paricalcitol and analyzed the ensuing fibrosis. The treatment reduced peritoneal IL-17 levels, which strongly correlated with a significantly lower peritoneal fibrotic response. In vitro studies demonstrate that both CD4+ and CD8+ regulatory T cells appear to impact the regulation of IL-17. Paricalcitol treatment resulted in a significantly increased frequency of CD8+ T cells showing a regulatory phenotype. The frequency of CD4+ Tregs tends to be increased, but it did not achieve statistical significance. However, paricalcitol treatment increased the number of CD4+ and CD8+ Treg cells in vivo. In conclusion, the activation of immunological regulatory mechanisms by VDR signaling could prevent or reduce fibrosis, as shown in peritoneal fibrosis induced by PDF exposure in mice.


  • Open Access

    IL-17A is a novel player in dialysis-induced peritoneal damage

    by Raquel Rodrigues-Díez, Luiz S. Aroeira, Macarena Orejudo, M-Auxiliadora Bajo, José Jiménez Heffernan, Raúl R Rodrigues-Díez, Sandra Rayego-Mateos, Alberto Ortiz, Guadalupe Gonzalez-Mateo, Manuel López-Cabrera, et al.


  • Open Access

    TWEAK Promotes Peritoneal Inflammation

    by Ana Belen Sanz, Luiz Stark Aroeira, Teresa Bellon, Gloria del Peso, Jose Jimenez-Heffernan, Beatriz Santamaria, Maria Dolores Sanchez-Niño, Luis Miguel Blanco-Colio, Manuel Lopez-Cabrera, Marta Ruiz-Ortega, et al.

    Peritoneal dialysis (PD) is complicated by peritonitis episodes that cause loss of mesothelium and eventually sclerosing peritonitis. An improved understanding of the molecular contributors to peritoneal injury and defense may increase the therapeutic armamentarium to optimize peritoneal defenses while minimizing peritoneal injury. There is no information on the expression and function of the cytokine TWEAK and its receptor Fn14 during peritoneal injury. Fn14 expression and soluble TWEAK levels were measured in human PD peritoneal effluent cells or fluids with or without peritonitis. Fn14 expression was also analyzed in peritoneal biopsies from PD patients. Actions of intraperitoneal TWEAK were studied in mice in vivo. sTWEAK levels were increased in peritoneal effluent in PD peritonitis. Effluent sTWEAK levels correlated with the number of peritoneal macrophages (r = 0.491, p = 0.002). Potential TWEAK targets that express the receptor Fn14 include mesothelial cells and macrophages, as demonstrated by flow cytometry of peritoneal effluents and by analysis of peritoneal biopsies. Peritoneal biopsy Fn14 correlated with mesothelial injury, fibrosis and inflammation, suggesting a potential deleterious effect of TWEAK/Fn14. In this regard, intraperitoneal TWEAK administration to mice promoted peritoneal inflammation characterized by increased peritoneal effluent MCP-1, Fn14 and Gr1+ macrophages, increased mesothelial Fn14, MCP-1 and CCL21 expression and submesothelial tissue macrophage recruitment. Taken together these data suggest that the TWEAK/Fn14 system may promote inflammation and tissue injury during peritonitis and PD.


  • The C-terminal module IV of connective tissue growth factor is a novel immune modulator of the Th17 response

    by Raquel Rodrigues-Díez, Raúl R Rodrigues-Díez, Sandra Rayego-Mateos, Beatriz Suarez-Alvarez, Carolina Lavoz, Luiz Stark Aroeira, Elsa Sánchez-López, Macarena Orejudo, Matilde Alique, Carlos Lopez-Larrea, et al.


  • Open Access

    TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab

    by Celia Oreja-Guevara, Jaime Ramos-Cejudo, Luiz Stark Aroeira, Beatriz Chamorro, Exuperio Diez-Tejedor

    The balance between T helper cells Th2- and Th1-related cytokines plays a key role in multiple sclerosis (MS). A shift from a Th1 towards a Th2 cytokine profile could have a beneficial effect on the clinical course of the disease. The objective of this study was to assess Th2/Th1 cytokine profile in relapsing-remitting MS (RRMS) patients receiving an immunosuppressive treatment with natalizumab (NAT), or an immunomodulatory treatment with glatiramer acetate (GA) after one year of treatment.


  • Influence of Bicarbonate/Low-GDP Peritoneal Dialysis Fluid (Bicavera) on in Vitro and Ex Vivo Epithelial-to-Mesenchymal Transition of Mesothelial Cells

    by Antonio Fernández–Perpén, María Luisa Pérez–Lozano, María–Auxiliadora Bajo, Patricia Albar–Vizcaino, Pilar Sandoval Correa, Gloria Del Peso, María–José Castro, Abelardo Aguilera, Marta Ossorio, Mirjam E. Peter, et al.

    Background: Peritoneal membrane damage induced by peritoneal dialysis (PD) is largely associated with epithelial-to-mesenchymal transition (EMT) of mesothelial cells (MCs), which is believed to be a result mainly of the glucose degradation products (GDPs) present in PD solutions. Objectives: This study investigated the impact of bicarbonate-buffered, low-GDP PD solution (BicaVera: Fresenius Medical Care, Bad Homburg, Germany) on EMT of MCs in vitro and ex vivo. Methods: studies: Omentum-derived MCs were incubated with lactate-buffered standard PD fluid or Bica-Vera fluid diluted 1:1 with culture medium. Ex vivo studies: From 31 patients randomly distributed to either standard or BicaVera solution and followed for 24 months, effluents were collected every 6 months for determination of EMT markers in effluent MCs. Results: Culturing of MCs with standard fluid in vitro resulted in morphology change to a non-epithelioid shape, with downregulation of E-cadherin (indicative of EMT) and strong induction of vascular endothelial growth factor (VEGF) expression. By contrast, in vitro exposure of MCs to bicarbonate/low-GDP solution had less impact on both EMT parameters. Ex vivo studies partially confirmed the foregoing results. The BicaVera group, with a higher prevalence of the non-epithelioid MC phenotype at baseline (for unknown reasons), showed a clear and significant trend to gain and maintain an epithelioid phenotype at medium- and longer-term and to show fewer fibrogenic characteristics. By contrast, the standard solution group demonstrated a progressive and significantly higher presence of the non-epithelioid phenotype. Compared with effluent MCs having an epithelioid phenotype, MCs with non-epithelioid morphology showed significantly lower levels of E-cadherin and greater levels of fibronectin and VEGF. In comparing the BicaVera and standard solution groups, MCs from the standard solution group showed significantly higher secretion of interleukin 8 and lower secretion of collagen I, but no differences in the levels of other EMT-associated molecules, including fibronectin, VEGF, E-cadherin, and transforming growth factor β1. Peritonitis incidence was similar in both groups. Functionally, the use of BicaVera fluid was associated with higher transport of small molecules and lower ultrafiltration capacity. Conclusions: Effluent MCs grown ex vivo from patients treated with bicarbonate/low-GDP BicaVera fluid showed a trend to acquire an epithelial phenotype, with lower production of proinflammatory cytokines and chemokines (such as interleukin 8) than was seen with MCs from patients treated with a lactate-buffered standard PD solution.